Abbott falls on plant QSR (US quality system regulation) failure
This article was originally published in Clinica
Shares in Abbott Laboratories dropped by over 9% last week on the release of an FDA report that found that its Lake County, Illinois, diagnostic plant still failed to meet US quality system regulation (QSR) standards. The plant, which produces lab and hospital blood tests among a range of 400 medical products, had been visited in January 2002 (see Clinica No 994, p 15). This followed an FDA consent decree in 1999, in which Abbott was fined $100 million and had a slew of products removed from the market (see Clinica No 883, p 1).
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.